atorvastatin + anakinra

Atorvastatin + anakinra is a combination therapy under investigation for the treatment of coronary artery abnormalities in children with acute Kawasaki disease (KD). Atorvastatin is a small molecule statin that inhibits HMG-CoA reductase, leading to reduced cholesterol synthesis and exerting anti-inflammatory effects at the vascular wall. Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra) that blocks IL-1-mediated inflammatory signaling by competitively inhibiting IL-1 alpha and beta binding to the IL-1 receptor. The rationale for this combination is based on their complementary anti-inflammatory mechanisms—atorvastatin reduces general vascular inflammation, while anakinra specifically targets IL-1-driven inflammation implicated in KD pathogenesis. This combination has been studied in early-phase clinical trials to assess safety and potential efficacy in preventing or attenuating coronary artery damage in pediatric KD patients[1][5][9].

Other names

atorvastatin and anakinra